目的 发现河南省药品生产企业在GMP认证方面存在的共性问题,对药品生产企业存在的主要风险点进行分析,并提出措施和建议,为新修订《药品管理法》的实施提供参考。方法 对河南省210份GMP认证现场检查报告中的缺陷项目进行统计分析。结果与结论 新修订《药品管理法》实施后,药品生产企业需要关注质量控制与质量保证、文件管理、设备等方面存在的问题,有针对性地进行持续改进和提升。药品监管部门通过转变监管模式,提高检查频次等方式加强监管,防止药品安全事故的发生。
Abstract
OBJECTIVE To discover the common deficiency in GMP certification existing in pharmaceutical enterprises of Henan Province, analyze the existing main risk point, offer some measures and suggestions and provide reference for implementing the newly revised Drug Administration Law. METHODS All defective items found in the 210 on-site inspection reports for GMP certification of pharmaceutical enterprises were statistically analyzed. RESULTS AND CONCLUSION After the implementation of the newly revised Drug Administration Law, drug manufacturers need to pay attention to the problems in quality control and quality assurance, document management, equipment and other aspects, and make continuous improvement and promotion accordingly. Drug regulatory departments enhance supervision by changing the supervision mode and increasing the inspection frequency and prevent the occurrence of drug safety accidents.
关键词
GMP认证 /
缺陷 /
分析 /
建议 /
药品管理法
{{custom_keyword}} /
Key words
GMP certification /
defect /
analysis /
recommendation /
drug administration law
{{custom_keyword}} /
中图分类号：
R95
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] CAO H Y, HAN Y. Analysis on defective items of drug GMP certification inspection for Shandong Province in 2017[J]. J Pharm Res(药学研究), 2018, 37(8):490-492.
[2] WANG L, ZHAO H J, MA H, et al. On defective items according to 2010 edition GMP certification in Liaoning Province [J]. Chin Pharm Aff(中国药事), 2017, 31(5):520-523.
[3] QIAN L W, LUO J J, WANG H, et al. Main problems of quality control and quality assurance in drug GMP inspection and the suggestions[J]. Chin Pharm Aff(中国药事), 2020, 34(1):17-21.
[4] LIU Y, YANG D Y, LI Y, et al. Problems and countermeasures of drug GMP certification inspection for Hebei province in 2018[J]. Chin J Clin Rat Drug Use(临床合理用药), 2019, 12(8):175-176.
[5] European Union Good Manufacturing Practice(欧盟药品生产质量管理规范)[S/OL].2011-02-11[2016-09-10]. http://ec. europa. eu/health/documents/eudralex/vol-4/index_en. Htm.
[6] Certification Committee for Drugs of China Food and Drug Administration (CFDA, CCD). Guidance of Good Manufacturing Practice for Drug[M]. Version 1. Beijing: China Medical Science and Technology Press, 2011.
[7] YOU D, CHEN Y N. The importance of personnel training in GMP management of pharmaceutical enterprises[J]. Yunnan Sci Technol Manage(云南科技管理), 2006, 19(3):37-38.
[8] ZHANG W Q, XIE Z L, DANG M A, et al. On defects in the implementation of new edition GMP for drugs in medical oxygen production enterprises in Henan Province [J]. Chin Pharm Aff(中国药事), 2017, 31(5):515-519.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1132 KB)
